All In Biotech

Drug Trial Radar · NCT02135419

Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions

ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study

Last checked: Nov 19, 2026Latest source record: Jul 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,446 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,446

Actual

Start

Sep 24, 2014

Primary completion

Aug 6, 2021

Study completion Mar 31, 2024

Sponsor

Lead sponsor
AIDS Malignancy ConsortiumResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI); The Emmes Company, LLC; University of Arkansas; University of California, San Francisco; University of Arizona
First posted
May 12, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The randomized phase of the trial compared topical or ablative treatment with active monitoring in preventing anal cancer in patients with human immunodeficiency virus (HIV) and high-grade squamous intraepithelial lesions (HSIL). Anal HSIL is tissue in the anal canal that has been damaged by infection with human papillomavirus (HPV) and is at risk for turning into anal cancer. The ANCHOR Data Safety Monitoring Board (DSMB) determined that the primary study endpoint was completed, based on the data and statistical analysis presented to them on 07SEP2021. In the post-randomization phase of this trial, all enrolled participants are offered treatment for HSIL and/or follow-up, at the participant's choice.

Conditions

  • Anal Cancer
  • High-grade Squamous Intraepithelial Lesion
  • HIV Infection
  • Human Papilloma Virus Infection

Interventions

  • imiquimodDrug

    Applied topically

  • fluorouracilDrug

    Applied topically

  • infrared photocoagulation therapyDevice

    Undergo infrared coagulation

  • thermal ablation therapyDevice

    Undergo hyfrecation/electrocautery therapy

  • laser therapyDevice

    Undergo laser therapy

  • clinical observationOther

    Undergo active monitoring (High Resolution Anoscopy \[HRA\]) with biopsies

  • laboratory biomarker analysisOther

    Correlative studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Anal Cancer IncidenceTime frame: Time from randomization to diagnosis of anal cancer, assessed up to 5 years post randomization

Locations

25 sites in 2 countries. Site status is shown where the registry gives one.

  • UCLA CARE Clinic

    Los Angeles, California

  • UCLA School of Nursing

    Los Angeles, California

  • DAP Health

    Palm Springs, California

  • University of California at San Francisco Anal Dysplasia Clinic

    San Francisco, California

  • University of Colorado Hospital

    Aurora, Colorado

  • Denver Public Health

    Denver, Colorado

  • Capital Digestive Care

    Washington D.C., District of Columbia

  • Dupont Circle Physicians Group

    Washington D.C., District of Columbia

  • ACC Clinic, Jackson Hospital

    Miami, Florida

  • University of Miami Miller School of Medicine - Sylvester Cancer Center

    Miami, Florida

  • Grady Health System

    Atlanta, Georgia

  • Anal Dysplasia Clinic MidWest

    Chicago, Illinois

  • University Medical Center New Orleans

    New Orleans, Louisiana

  • CrescentCare Health

    New Orleans, Louisiana

  • Boston Medical Center

    Boston, Massachusetts

  • Fenway Health

    Boston, Massachusetts

  • Rutgers University New Jersey Medical School

    Newark, New Jersey

  • Cornell Clinical Trials Unit, Chelsea Center

    New York, New York

  • Laser Surgery Care

    New York, New York

  • Montefiore - Albert Einstein College of Medicine

    The Bronx, New York

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina

  • Virginia Mason Medical Center

    Seattle, Washington

  • Harborview Medical Center

    Seattle, Washington

  • The Polyclinic

    Seattle, Washington

  • University of Puerto Rico

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.